Your browser is no longer supported. Please, upgrade your browser.
Settings
ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-1.11 Insider Own1.30% Shs Outstand137.00M Perf Week-25.35%
Market Cap5.75B Forward P/E- EPS next Y-1.49 Insider Trans-82.84% Shs Float128.95M Perf Month-29.17%
Income-146.20M PEG- EPS next Q-0.37 Inst Own83.10% Short Float2.35% Perf Quarter-11.45%
Sales98.40M P/S58.42 EPS this Y-100.60% Inst Trans2.46% Short Ratio3.33 Perf Half Y1.05%
Book/sh5.43 P/B7.78 EPS next Y0.70% ROA-14.80% Target Price66.40 Perf Year53.45%
Cash/sh5.06 P/C8.35 EPS next 5Y2.20% ROE-22.50% 52W Range15.19 - 71.25 Perf YTD-28.58%
Dividend- P/FCF- EPS past 5Y- ROI-20.60% 52W High-40.73% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin77.10% 52W Low178.01% ATR4.24
Employees622 Current Ratio6.90 Sales Q/Q24.80% Oper. Margin- RSI (14)26.54 Volatility10.19% 6.83%
OptionableYes Debt/Eq0.00 EPS Q/Q-97.70% Profit Margin- Rel Volume2.33 Prev Close43.68
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 AMC Payout- Avg Volume907.60K Price42.23
Recom1.60 SMA20-28.26% SMA50-30.04% SMA200-13.68% Volume2,113,235 Change-3.32%
Mar-03-21Downgrade Goldman Buy → Neutral $74 → $63
Oct-08-20Resumed BTIG Research Buy $60
Sep-09-20Initiated Morgan Stanley Equal-Weight $42
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Mar-07-21 02:52AM  
Mar-05-21 06:44PM  
Feb-27-21 02:30PM  
Feb-25-21 04:05PM  
Feb-24-21 11:00PM  
05:32PM  
04:05PM  
Feb-23-21 12:42PM  
09:15AM  
07:30AM  
Feb-10-21 11:25PM  
Feb-02-21 04:05PM  
Feb-01-21 09:14AM  
Jan-21-21 09:00AM  
Jan-18-21 09:12AM  
Jan-12-21 08:15AM  
Jan-11-21 04:01PM  
Jan-06-21 10:53AM  
Dec-30-20 04:30PM  
08:51AM  
Dec-06-20 10:00AM  
Nov-23-20 08:00AM  
Nov-19-20 06:32AM  
Nov-13-20 08:00AM  
Nov-11-20 05:21AM  
05:00AM  
Nov-10-20 05:25PM  
05:22PM  
04:13PM  
04:10PM  
Nov-03-20 12:30PM  
Oct-28-20 05:30PM  
Oct-13-20 04:05PM  
Sep-28-20 10:52AM  
Sep-01-20 04:03PM  
Aug-11-20 01:01AM  
Aug-10-20 06:35PM  
04:05PM  
12:44PM  
08:05AM  
Aug-06-20 09:24AM  
Aug-04-20 09:30AM  
Jul-30-20 06:19AM  
Jul-28-20 06:04PM  
Jul-16-20 12:00PM  
Jul-15-20 07:47PM  
Jul-14-20 04:44PM  
Jul-09-20 04:29PM  
08:05AM  
Jun-23-20 11:54AM  
Jun-17-20 08:56AM  
Jun-15-20 10:27AM  
Jun-11-20 09:00AM  
Jun-08-20 04:03PM  
Jun-07-20 06:25AM  
May-27-20 04:03PM  
May-19-20 08:03AM  
May-18-20 02:47PM  
May-14-20 11:51AM  
May-13-20 12:31PM  
07:02AM  
May-12-20 04:03PM  
08:06AM  
May-11-20 10:57AM  
09:57AM  
May-08-20 09:09AM  
May-06-20 03:06PM  
02:50PM  
12:10PM  
08:19AM  
08:00AM  
May-05-20 12:00PM  
Apr-30-20 08:51AM  
06:39AM  
Apr-27-20 04:03PM  
Apr-20-20 08:15AM  
Apr-17-20 09:13PM  
12:40PM  
Apr-15-20 04:47PM  
08:26AM  
Apr-09-20 07:45PM  
Apr-07-20 08:35PM  
Apr-05-20 10:14AM  
Apr-03-20 10:51AM  
Apr-02-20 07:58PM  
05:50PM  
04:23PM  
04:04PM  
12:29PM  
09:34AM  
09:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:45PM  
Mar-23-20 11:06AM  
Mar-20-20 02:00PM  
01:02PM  
Feb-29-20 07:12AM  
Feb-27-20 05:54PM  
Feb-26-20 04:05PM  
Feb-21-20 10:20AM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pellini Michael JDirectorMar 01Option Exercise6.5520,000131,00020,000Mar 03 07:00 PM
BENZENO SHARONChief Business Development OffMar 01Option Exercise6.726,77145,4756,771Mar 03 07:00 PM
RUBINSTEIN JULIEPresidentMar 01Option Exercise6.5515,00098,25015,000Mar 03 07:00 PM
Pellini Michael JDirectorMar 01Sale57.8020,0001,156,0000Mar 03 07:00 PM
BENZENO SHARONChief Business Development OffMar 01Sale57.626,771390,1430Mar 03 07:00 PM
RUBINSTEIN JULIEPresidentMar 01Sale58.3215,000874,7430Mar 03 07:00 PM
Taylor Stacy LSVP and General CounselFeb 26Option Exercise7.012,81219,7204,112Mar 01 08:00 PM
RUBINSTEIN JULIEPresidentFeb 26Option Exercise6.5515,00098,25015,000Mar 01 09:00 PM
Taylor Stacy LSVP and General CounselFeb 26Sale55.532,812156,1381,300Mar 01 08:00 PM
RUBINSTEIN JULIEPresidentFeb 26Sale56.2315,000843,4500Mar 01 09:00 PM
RUBINSTEIN JULIEPresidentFeb 25Option Exercise6.5514,67596,12114,675Feb 26 06:00 PM
RUBINSTEIN JULIEPresidentFeb 25Sale56.1814,675824,4270Feb 26 06:00 PM
RUBINSTEIN JULIEPresidentFeb 24Option Exercise6.5515,00098,25015,000Feb 26 06:00 PM
RUBINSTEIN JULIEPresidentFeb 24Sale57.7815,000866,6290Feb 26 06:00 PM
RUBINSTEIN JULIEPresidentFeb 23Option Exercise6.5515,00098,25015,000Feb 24 09:00 PM
RUBINSTEIN JULIEPresidentFeb 23Sale55.4515,000831,7900Feb 24 09:00 PM
RUBINSTEIN JULIEPresidentFeb 22Option Exercise6.5515,00098,25015,000Feb 24 09:00 PM
RUBINSTEIN JULIEPresidentFeb 22Sale59.7115,000895,6210Feb 24 09:00 PM
RUBINSTEIN JULIEPresidentFeb 19Option Exercise6.5515,00098,25015,000Feb 22 07:00 PM
BENZENO SHARONChief Business Development OffFeb 19Option Exercise6.274162,608416Mar 03 07:00 PM
RUBINSTEIN JULIEPresidentFeb 19Sale62.2915,000934,3650Feb 22 07:00 PM
BENZENO SHARONChief Business Development OffFeb 19Sale61.2041625,4590Mar 03 07:00 PM
RUBINSTEIN JULIEPresidentFeb 18Option Exercise6.5515,00098,25015,000Feb 19 08:00 PM
RUBINSTEIN JULIEPresidentFeb 18Sale60.9215,000913,8170Feb 19 08:00 PM
RUBINSTEIN JULIEPresidentFeb 17Option Exercise6.5515,00098,25015,000Feb 19 08:00 PM
RUBINSTEIN JULIEPresidentFeb 17Sale62.0515,000930,8190Feb 19 08:00 PM
LO FRANCISChief People OfficerFeb 16Option Exercise7.802,00015,6002,000Feb 17 08:01 PM
RUBINSTEIN JULIEPresidentFeb 16Option Exercise6.5515,00098,25015,000Feb 17 08:01 PM
Taylor Stacy LSVP and General CounselFeb 16Option Exercise31.7116,250515,28817,550Feb 17 08:01 PM
BENZENO SHARONChief Business Development OffFeb 16Option Exercise31.7116,250515,28816,250Feb 17 08:01 PM
HERSHBERG ROBERTDirectorFeb 16Option Exercise0.452,0009003,504Feb 17 08:00 PM
GRIFFIN MICHELLE RENEEDirectorFeb 16Option Exercise7.806,00046,8007,504Feb 16 08:26 PM
LO FRANCISChief People OfficerFeb 16Sale65.452,000130,9000Feb 17 08:01 PM
RUBINSTEIN JULIEPresidentFeb 16Sale65.2515,000978,7500Feb 17 08:01 PM
Taylor Stacy LSVP and General CounselFeb 16Sale64.6416,2501,050,3271,300Feb 17 08:01 PM
BENZENO SHARONChief Business Development OffFeb 16Sale64.6416,2501,050,3810Feb 17 08:01 PM
HERSHBERG ROBERTDirectorFeb 16Sale65.452,000130,9001,504Feb 17 08:00 PM
GRIFFIN MICHELLE RENEEDirectorFeb 16Sale65.086,000390,4801,504Feb 16 08:26 PM
RUBINSTEIN JULIEPresidentFeb 12Option Exercise6.5515,00098,25015,000Feb 17 08:01 PM
RUBINSTEIN JULIEPresidentFeb 12Sale65.9815,000989,6820Feb 17 08:01 PM
RUBINSTEIN JULIEPresidentFeb 11Option Exercise6.5515,00098,25015,000Feb 12 08:00 PM
RUBINSTEIN JULIEPresidentFeb 11Sale63.2815,000949,1490Feb 12 08:00 PM
RUBINSTEIN JULIEPresidentFeb 10Option Exercise6.5515,00098,25015,000Feb 12 08:00 PM
ROBINS CHAD MCEO and ChairmanFeb 10Sale62.7610,000627,6481,709,780Feb 10 09:00 PM
RUBINSTEIN JULIEPresidentFeb 10Sale62.9615,000944,4050Feb 12 08:00 PM
RUBINSTEIN JULIEPresidentFeb 09Option Exercise6.4715,00097,10015,000Feb 10 09:00 PM
ROBINS CHAD MCEO and ChairmanFeb 09Sale62.5510,000625,5261,719,780Feb 10 09:00 PM
RUBINSTEIN JULIEPresidentFeb 09Sale62.4115,000936,0910Feb 10 09:00 PM
RUBINSTEIN JULIEPresidentFeb 08Option Exercise6.3215,00094,80015,000Feb 10 09:00 PM
ROBINS CHAD MCEO and ChairmanFeb 08Sale61.6110,000616,1491,729,780Feb 10 09:00 PM
RUBINSTEIN JULIEPresidentFeb 08Sale62.1015,000931,4420Feb 10 09:00 PM
RUBINSTEIN JULIEPresidentFeb 05Option Exercise6.3215,00094,80015,000Feb 08 09:00 PM
RUBINSTEIN JULIEPresidentFeb 05Sale59.9615,000899,3280Feb 08 09:00 PM
RUBINSTEIN JULIEPresidentFeb 04Option Exercise6.3215,00094,80015,000Feb 05 06:00 PM
RUBINSTEIN JULIEPresidentFeb 04Sale58.9815,000884,7640Feb 05 06:00 PM
RUBINSTEIN JULIEPresidentFeb 03Option Exercise6.3215,00094,80015,000Feb 05 06:00 PM
ROBINS HARLAN SChief Scientific OfficerFeb 03Option Exercise6.327,79049,2338,469Feb 05 06:00 PM
RUBINSTEIN JULIEPresidentFeb 03Sale59.7615,000896,3360Feb 05 06:00 PM
ROBINS HARLAN SChief Scientific OfficerFeb 03Sale59.587,790464,158679Feb 05 06:00 PM
RUBINSTEIN JULIEPresidentFeb 02Option Exercise6.3215,00094,80015,000Feb 03 08:00 PM
ROBINS HARLAN SChief Scientific OfficerFeb 02Option Exercise6.327,79049,2338,469Feb 03 08:00 PM
RUBINSTEIN JULIEPresidentFeb 02Sale58.9915,000884,8080Feb 03 08:00 PM
ROBINS HARLAN SChief Scientific OfficerFeb 02Sale59.657,790464,647679Feb 03 08:00 PM
RUBINSTEIN JULIEPresidentFeb 01Option Exercise6.3215,00094,80015,000Feb 03 08:00 PM
ROBINS HARLAN SChief Scientific OfficerFeb 01Option Exercise6.327,79049,2338,469Feb 03 08:00 PM
BENZENO SHARONChief Business Development OffFeb 01Option Exercise6.726,77045,4686,770Feb 03 08:00 PM
RUBINSTEIN JULIEPresidentFeb 01Sale55.5415,000833,0360Feb 03 08:00 PM
ROBINS HARLAN SChief Scientific OfficerFeb 01Sale55.837,790434,954679Feb 03 08:00 PM
BENZENO SHARONChief Business Development OffFeb 01Sale55.656,770376,7200Feb 03 08:00 PM
Taylor Stacy LSVP and General CounselJan 29Option Exercise7.012,81319,7284,113Feb 01 08:00 PM
RUBINSTEIN JULIEPresidentJan 29Option Exercise6.3215,00094,80015,000Feb 01 08:00 PM
Cohen Chad MChief Financial OfficerJan 29Option Exercise6.3250,000316,00051,000Feb 01 08:00 PM
Taylor Stacy LSVP and General CounselJan 29Sale56.512,813158,9591,300Feb 01 08:00 PM
RUBINSTEIN JULIEPresidentJan 29Sale56.2815,000844,1630Feb 01 08:00 PM
Cohen Chad MChief Financial OfficerJan 29Sale56.0350,0002,801,5461,000Feb 01 08:00 PM
RUBINSTEIN JULIEPresidentJan 28Option Exercise6.3215,00094,80015,000Jan 29 08:00 PM
Cohen Chad MChief Financial OfficerJan 28Option Exercise6.3250,000316,00051,000Feb 01 08:00 PM
RUBINSTEIN JULIEPresidentJan 28Sale55.8315,000837,5130Jan 29 08:00 PM
Cohen Chad MChief Financial OfficerJan 28Sale56.2250,0002,811,0551,000Feb 01 08:00 PM
ROBINS CHAD MCEO and ChairmanJan 28Sale56.9110,000569,1231,739,780Jan 28 07:19 PM
RUBINSTEIN JULIEPresidentJan 27Option Exercise6.3215,00094,80015,000Jan 29 08:00 PM
BALDO LANCEChief Medical OfficerJan 27Option Exercise7.8040,000312,00040,000Jan 29 08:00 PM
RUBINSTEIN JULIEPresidentJan 27Sale58.9415,000884,0670Jan 29 08:00 PM
BALDO LANCEChief Medical OfficerJan 27Sale58.9540,0002,358,1170Jan 29 08:00 PM
ROBINS CHAD MCEO and ChairmanJan 27Sale57.7110,000577,1371,749,780Jan 28 07:19 PM
Cohen Chad MChief Financial OfficerJan 26Option Exercise6.3250,000316,00051,000Jan 27 07:00 PM
RUBINSTEIN JULIEPresidentJan 26Option Exercise6.3215,00094,80015,000Jan 27 07:00 PM
Cohen Chad MChief Financial OfficerJan 26Sale64.0450,0003,202,0741,000Jan 27 07:00 PM
RUBINSTEIN JULIEPresidentJan 26Sale64.6115,000969,0790Jan 27 07:00 PM
ROBINS CHAD MCEO and ChairmanJan 26Sale63.5310,000635,2861,759,780Jan 28 07:19 PM
Cohen Chad MChief Financial OfficerJan 25Option Exercise6.3250,000316,00051,000Jan 27 07:00 PM
RUBINSTEIN JULIEPresidentJan 25Option Exercise6.3215,00094,80015,000Jan 27 07:00 PM
Cohen Chad MChief Financial OfficerJan 25Sale66.0750,0003,303,3821,000Jan 27 07:00 PM
RUBINSTEIN JULIEPresidentJan 25Sale66.4315,000996,4300Jan 27 07:00 PM
RUBINSTEIN JULIEPresidentJan 22Option Exercise6.3215,00094,80015,000Jan 25 07:00 PM
RUBINSTEIN JULIEPresidentJan 22Sale66.8415,0001,002,5470Jan 25 07:00 PM
RUBINSTEIN JULIEPresidentJan 21Option Exercise6.3215,00094,80015,000Jan 22 07:00 PM
ROBINS HARLAN SChief Scientific OfficerJan 21Option Exercise6.3223,370147,69824,049Jan 25 07:00 PM
RUBINSTEIN JULIEPresidentJan 21Sale66.5615,000998,4450Jan 22 07:00 PM
ROBINS HARLAN SChief Scientific OfficerJan 21Sale66.8223,3701,561,592679Jan 25 07:00 PM